Rani Therapeutics (RANI) Expected to Announce Quarterly Earnings on Wednesday

Rani Therapeutics (NASDAQ:RANI - Get Free Report) is expected to release its earnings data before the market opens on Wednesday, March 19th. Analysts expect Rani Therapeutics to post earnings of ($0.24) per share for the quarter.

Rani Therapeutics Trading Down 1.4 %

NASDAQ RANI opened at $1.46 on Wednesday. The stock has a market cap of $83.64 million, a P/E ratio of -1.38 and a beta of 0.14. Rani Therapeutics has a fifty-two week low of $1.24 and a fifty-two week high of $8.75. The stock has a 50 day simple moving average of $1.49 and a two-hundred day simple moving average of $1.96. The company has a debt-to-equity ratio of 2.34, a quick ratio of 1.60 and a current ratio of 1.60.

Wall Street Analyst Weigh In

Several analysts recently weighed in on RANI shares. HC Wainwright reiterated a "buy" rating and issued a $9.00 price target on shares of Rani Therapeutics in a report on Friday, February 7th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $9.00 target price on shares of Rani Therapeutics in a research note on Wednesday, February 26th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Rani Therapeutics currently has an average rating of "Buy" and an average target price of $12.33.

Insiders Place Their Bets

In other news, insider Kate Mckinley acquired 17,960 shares of the firm's stock in a transaction on Friday, December 13th. The stock was acquired at an average price of $1.67 per share, for a total transaction of $29,993.20. Following the completion of the acquisition, the insider now owns 17,960 shares in the company, valued at $29,993.20. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 53.30% of the stock is owned by corporate insiders.

Rani Therapeutics Company Profile

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads